Previously announced partnership with Tollo Health subsidiary TolloCare adding telehealth service offering to drive Wellgistics Pharmacy prescription drug dispending of GLP-1 drugs and promote patient engagement via mental health AI software solution for compliance and to promote lifestyle changes TAMPA, FL / ACCESS Newswire / February 18, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (' ...

Core Insights - The article discusses the strategic partnership between Wellgistics Health, Inc. and DataVault AI, Inc. to enhance the PharmacyChain platform using advanced technologies [1] - The partnership aims to leverage DataVault AI's edge network and quantum key encryption to improve data-driven outcomes in the $634 billion prescription drug market [1] Company Overview - Wellgistics Health, Inc. is a leader in health information technology, focusing on pharmacy dispensing optimization through its AI platform EinsteinRx [1] - DataVault AI, Inc. specializes in AI-driven data valuation, monetization, and secure tokenization within Web 3.0 environments [1] Technology Integration - The partnership will integrate DataVault AI's advanced technology platform into Wellgistics' PharmacyChain, enhancing its blockchain-enabled smart contracts and tokenization capabilities [1] - Quantum key encryption will fortify pharmacies against potential threats from quantum computing, which could compromise traditional encryption methods [1]

Core Insights - Wellgistics Health, Inc. is integrating its AI platform EinsteinRx into pharmacy point-of-sales systems to enhance prescription drug dispensing efficiency [1] - The company aims to onboard up to 500 pharmacies per month into the Wellgistics Pharmacy Network by the end of 2026 [1] - The focus of the manufacturer-supplier relationship expansion is on diabetes, weight loss, cardiometabolic, and Long COVID patients [1] - Wellgistics is assessing resources for the development of blockchain-enabled smart contracts through its PharmacyChain platform [1] - The company is entering a phase of hyper-focused operational execution under the leadership of President and Interim-CEO Prashant Patel [1]

Core Viewpoint - Wellgistics Health, Inc. is integrating its proprietary AI platform EinsteinRx into its blockchain-enabled smart contracts platform PharmacyChain, enhancing its position in health information technology [1] Group 1: Company Overview - Wellgistics Health, Inc. is a leader in health information technology [1] - The company is publicly traded on NASDAQ under the ticker symbol WGRX [1] Group 2: Product Integration - Wellgistics is combining its AI-driven pharmacy dispensing optimization platform EinsteinRx with its PharmacyChain platform [1] - This integration aims to improve efficiency and effectiveness in pharmacy operations [1] Group 3: Shareholder Information - The company has announced a record date of December 19, 2025, for shareholders to receive Dream Bowl 2026 Meme Coin tokens [1] - Eligible shareholders will receive one Dream Bowl token for each share of common stock owned [1]

Core Viewpoint - Wellgistics Health, Inc. has announced a record date of December 19, 2025, for shareholders to receive the Dream Bowl 2026 Meme Coin, with one coin distributed for each share owned [1] Company Overview - Wellgistics Health, Inc. is a leader in health information technology, focusing on the implementation of EinsteinRx™ artificial intelligence for prescription drug routing [1] - The company utilizes a blockchain-enabled smart contracts platform, PharmacyChain™, to enhance the reimbursement and dispensing process for prescription medicines [1]

Group 1 - The company plans to distribute Dream Bowl 2026 Meme Coin to shareholders with a record date and distribution date expected in December 2025 [1] - Distribution of the Meme Coin is anticipated to occur in January 2026 [1] - Wellgistics Health, Inc. is involved in the DataVault AI Shareholder Distribution Plan and is sponsoring Dream Bowl 2026 [1] Group 2 - Wellgistics is a leader in health information technology, utilizing EinsteinRx™ artificial intelligence for prescription routing [1] - The company employs PharmacyChain™ blockchain-enabled smart contracts to enhance the tracking and dispensing of prescription drugs [1] - The technology aims to optimize insurance coverage from manufacturers to patients [1]

Core Viewpoint - Wellgistics Health, Inc. reported its financial results for the period ended September 30, 2025, and provided a business update following the reappointment of Prashant Patel as President and Interim-CEO [1] Financial Results - The financial results were disclosed on Form 10-Q on November 19, 2025, indicating the company's performance metrics for the specified period [1] Business Update - The Interim-CEO highlighted that the last six weeks have provided insights into the various stages of development across different parts of the business since his reappointment on October 6, 2025 [1]

Core Viewpoint - Wellgistics Health, Inc. is set to report its third quarter 2025 financial results and provide a business update on November 20, 2025, highlighting its role in the healthcare technology sector focused on prescription drug distribution [1] Company Overview - Wellgistics Health, Inc. operates in the health information technology space, specifically optimizing the delivery of medications from manufacturers to patients through licensed pharmacies [1] - The company is publicly traded on NASDAQ under the ticker symbol WGRX [1]

Financial Performance - Solventum's total sales reached $2,096 million, with a reported increase of 0.7% year-over-year and an organic increase of 2.7% year-over-year[12] - MedSurg segment net sales were $1,206 million, reflecting a reported increase of 2.1% and an organic increase of 1.1% year-over-year[13, 17] - Dental Solutions segment net sales were $340 million, with a reported increase of 8.4% and an organic increase of 6.5% year-over-year[12, 24] - Health Information Systems segment net sales were $345 million, showing a reported increase of 5.9% and an organic increase of 5.6% year-over-year[12, 29] - Purification & Filtration segment net sales were $128 million, a reported decrease of 28.7% but an organic increase of 6.4% year-over-year, representing two months of sales before divestiture[12, 34] Profitability and Cash Flow - The company's GAAP operating margin was 80.6%, while the non-GAAP operating margin was 20.6%[13] - GAAP EPS was $7.22, and non-GAAP EPS was $1.50[13] - Cash from operations was $75 million, and free cash flow was negative $22 million[13] Guidance - The company expects organic sales growth of +2.0% to +3.0%, increasing to the high-end of range, or +2.5% to +3.5% excluding ~50bps of SKU-exit impact[39] - Adjusted EPS is expected to be $5.98 to $6.08, versus a prior range of $5.88 - $6.03[39] - Free cash flow is reduced to $150 million to $250 million from $450 million to $550 million due to the Purification & Filtration divestiture impact[39] - Net interest expense is estimated to be ~$360 million, with total non-operating expense around ~$400 million[40] Strategic Actions - The company completed the sale of the Purification & Filtration segment for approximately $4 billion, generating net proceeds of approximately $3.6 billion, with $2.7 billion used for debt reduction[34]

Core Points - Veradigm LLC, a health information technology company, announced a cybersecurity incident affecting the personal information of tens of thousands of individuals [1] - The breach involved unauthorized access to personally identifiable information (PII) including names, contact details, dates of birth, health records, health insurance information, payment details, Social Security numbers, and driver's license numbers [1] Legal Implications - Lynch Carpenter, LLP is investigating claims against Veradigm related to the data breach, indicating potential legal actions for affected individuals [2] - Individuals who received a data breach notification from Veradigm may be entitled to compensation [2] Company Background - Lynch Carpenter is a national class action law firm with a focus on data privacy matters, representing millions of clients over more than a decade [3]